Amgen Inc. has announced the initiation of early-stage clinical trials for a novel class of therapeutic molecules known as LOCKTACs. One such investigational medicine, AMG 193, is being tested as a potential first-in-class selective inhibitor of the enzyme PRMT5 for treating solid tumors lacking the MTAP gene. This trial aims to assess the efficacy of AMG 193 in stabilizing the interaction between PRMT5 and MTA, a natural metabolite, to inhibit tumor growth in MTAP-deleted cancer cells while minimizing toxicity to normal cells. The results of these trials have not yet been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.